Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Genelabs

This article was originally published in The Gray Sheet

Executive Summary

Enter agreement granting Abbott a worldwide, non-exclusive license to develop and commercialize diagnostic and screening products for "hepatitis X virus." Genelabs says the virus, which has not been characterized, "is believed to be an agent responsible for transfusion-transmitted hepatitis not caused by hepatitis B or C viruses." Under the agreement, Genelabs will receive from Abbott license and milestone payments that could exceed $10 mil., as well as royalties on sales by Abbott of HXV products. Genelabs retains the right to develop HXV confirmatory tests. The agreement builds on a similar deal between the two companies covering hepatitis E virus diagnostics products. Genelabs launched an HEV screening test in Asia in June ("The Gray Sheet" June 8, I&W-2)....
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel